The sales of medicines for obstructive airway diseases in Germany are forecasted to show a steady growth trend from 2024 to 2028, beginning at $3.17 billion and reaching $3.44 billion USD PPP. The compound annual growth rate (CAGR) over these five years is modest, indicating a stable demand increase for treatments related to obstructive airway diseases. In 2023, the sales stood at approximately a value slightly below $3.17 billion, setting a foundation for the forecasted growth path ahead.
Key future trends to monitor include the impact of emerging therapies and innovative drug delivery systems, potential changes in healthcare policies, and the influence of demographic shifts on disease prevalence. Additionally, advancements in personalized medicine could disrupt market dynamics, potentially altering growth trajectories beyond the current forecast period.
